Vaccine-derived Yellow Fever in an immunocompromised patient on anti-CD20-antibody therapy and its treatment with Sofosbuvir

Yellow fever (YF) is a potentially lethal viral hemorrhagic fever transmitted to humans by Haemagogous and Aedes spp., (mainly Aedes aegypti). The risk of a YF infection for unvaccinated people during a two week stay in West Africa is about 50:100.000 and 5:100.000 in South America. Case fatality rates reach up to 40-60% in South America but are estimated at 20% in Africa [1] ⁠. The 17D live attenuated YF vaccine, which was developed in 1937 by Max Theiler, proved to be a highly effective method in preventing an outbreak of the symptomatic disease, but can also cause severe adverse reactions like YF vaccine-associated neurotropic disease (YEL-AND) or YF vaccine-associa ted viscerotropic disease (YEL-AVD) [2]⁠.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Case Report Source Type: research